Anuh Pharma Limited

ANUHPHR6

INE489G01022

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 09:42:23 29/05/2024 am IST			5-day change	1st Jan Change
230.6 ^INR	-0.60%		-1.83%	+57.30%

17/05	Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
17/05	Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	CI

Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022

August 06, 2022 at 12:54 pm IST

Anuh Pharma Limited announced that at the AGM held on August 5, 2022 approved Final Dividend of INR 1.75/- per Equity Share of the Company for the financial year ended 2021-2022.

Latest news about Anuh Pharma Limited

Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	17/05	CI
Anuh Pharma Limited Recommends Dividend for the Financial Year Ended 31 March 2024	17/05	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2022-2023	08/04	CI
Anuh Pharma Limited Appoints Manan Jayesh Vadhan as Company Secretary and Compliance Officer	04/04	CI
Anuh Pharma Limited Announces Completion of Tenure of Jasvantlal Girdharlal Shah as Independent Director	01/04	CI
Anuh Pharma Gets European Regulator's Nod for Anti-Malarial Drug	28/02	MT
Anuh Pharma Limited Announces Resignation of Jinal Dharmil Mehtalia as Company Secretary and Compliance Officer, Effective 14 February, 2024	12/02	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	09/02	CI
Anuh Pharma Limited Announces the Resignation of Hemant Aunt as Company Secretary and Compliance Officer	11/01	CI
Anuh Pharma Limited Announces Appointment of Ms. Jinal Ajay Shah as Company Secretary and Compliance Officer, Effective from 15 January 2024	05/01	CI
Anuh Pharma Limited Approves the Board Appointments	13/12	CI
Anuh Pharma Limited Approves Board Appointments	10/11	CI
Anuh Pharma Limited Approves Board Appointments	19/23/19	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	11/23/11	CI
Anuh Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	19/23/19	CI
Anuh Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	19/23/19	CI
Anuh Pharma Limited Announces Board Changes	19/23/19	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2023	19/23/19	CI
Anuh Pharma Limited Announces Resignation of Lalitkumar P Shah as Non-Executive Director	10/23/10	CI
Anuh Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Anuh Pharma Limited Approves Appointment of Hemant Auti as the Company Secretary & Compliance Officer	06/23/06	CI
Anuh Pharma Limited Announces Resignation of Bharat Gangani as Company Secretary and Compliance Officer	20/22/20	CI
Anuh Pharma Limited Approves Final Dividend for the Financial Year Ended 2021-2022	06/22/06	CI
Anuh Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	05/22/05	CI
Anuh Pharma Limited Recommends Final Dividend for the Financial Year Ended 31 March 2022	14/22/14	CI

Anuh Pharma Limited is an India-based bulk drug manufacturing company. The Company is engaged in the business of manufacturing active pharmaceutical ingredients (API). The Company manufactures Macrolides, Anti-TB, Anti-Bacterials, Anti-Malarial, Anti-Hypertension, Expectorant and Corticosteroids products. Its Macrolides products include Erythromycin, Erythromycin Ethyl Succinate, Erythromycin Stearate, Erythromycin Estolate, Erythromycin Propionate, Erythromycin Phosphate, Erythromycin 11,12 Carbonate and Azithromycin. Its Anti-TB products include Pyrazinamide and Isoniazid. Its Anti-Malarial products include Sulfadoxine and Pyrimethamine. Anti-Bacterials products include Chloramphenicol and Chloramphenicol Palmitate. Anti-Hypertension products include Losartan Potassium, Telmisartan and Atorvastatin Calcium. Its Expectorant product includes Ambroxol Hydrochloride. Its Quinolones product includes Moxifloxacin Hydrochloride.

Sector

Pharmaceuticals

Calendar

09/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ANUH PHARMA LIMITED	+57.30%	14Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+16.50%	4.23TCr
OTSUKA HOLDINGS CO., LTD.	+15.54%	2.13TCr
SANDOZ GROUP AG	+19.33%	1.53TCr
CIPLA LIMITED	+18.75%	1.44TCr
ZYDUS LIFESCIENCES LIMITED	+50.99%	1.28TCr
THE MEDICINES COMPANY	-0.05%	678.76Cr
ONO PHARMACEUTICAL CO., LTD.	-12.04%	658.31Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+14.28%	550.82Cr